Department of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
Cardiology Department, Centre Cardiologique du Nord, Saint-Denis, France.
J Am Coll Cardiol. 2023 Nov 14;82(20):1889-1902. doi: 10.1016/j.jacc.2023.08.044. Epub 2023 Oct 23.
Current guidelines recommend selecting surgical aortic valve replacement (SAVR) or transcatheter aortic valve replacement (TAVR) based on age, comorbidities, and surgical risk. Nevertheless, reports from the United States suggest a rapid expansion of TAVR in young patients.
The authors sought to evaluate the trends in TAVR uptake at a nationwide level in France according to age and sex.
Using a nationwide administrative database, we evaluated age- and sex-related trends in TAVR uptake, patient demographics, and in-hospital outcomes between 2015 and 2020.
A total of 107,397 patients (44.0% female) underwent an isolated aortic valve replacement (AVR) (59.1% TAVR, 40.9% SAVR). In patients <65 years of age, the proportion of TAVR increased by 63.2% (P < 0.001) from 2015 to 2020 but remained uncommon at 11.1% of all AVR by 2020 (12.4% in females, 10.6% in males) while TAVR was the dominant modality in patients ≥65 years of age. In patients undergoing TAVR, the Charlson comorbidity index (CCI) (P = 0.119 for trend) and in-hospital mortality (P = 0.740 for trend) remained unchanged in patients <65 years of age but declined in those ≥65 years of age irrespective of sex (all P < 0.001 for trends). Females were older (P < 0.001), had lower CCI (P < 0.001), were more likely to undergo TAVR (P < 0.001), and experienced higher in-hospital mortality (TAVR, P = 0.015; SAVR, P < 0.001) that persisted despite adjustment for age and CCI.
In France, the use of TAVR remained uncommon in young patients, predominantly restricted to those at high risk. Important sex differences were observed in patent demographics, selection of AVR modality, and patient outcomes. Additional research evaluating the long-term impact of TAVR use in young patients and prospective data evaluating sex differences in AVR modality selection and outcomes are needed.
目前的指南建议根据年龄、合并症和手术风险选择主动脉瓣置换术(SAVR)或经导管主动脉瓣置换术(TAVR)。然而,来自美国的报告表明,TAVR 在年轻患者中的应用迅速扩大。
作者旨在评估法国全国范围内根据年龄和性别接受 TAVR 的趋势。
使用全国性行政数据库,我们评估了 2015 年至 2020 年期间 TAVR 接受率、患者人口统计学特征和住院结局的年龄和性别相关趋势。
共有 107397 名患者(44.0%为女性)接受了单纯主动脉瓣置换术(AVR)(59.1%为 TAVR,40.9%为 SAVR)。在<65 岁的患者中,TAVR 的比例从 2015 年到 2020 年增加了 63.2%(P<0.001),但到 2020 年仅占所有 AVR 的 11.1%(女性为 12.4%,男性为 10.6%),而 TAVR 是≥65 岁患者的主要治疗方式。在接受 TAVR 的患者中,Charlson 合并症指数(CCI)(趋势 P=0.119)和住院死亡率(趋势 P=0.740)在<65 岁的患者中保持不变,但在≥65 岁的患者中无论性别如何均下降(所有 P<0.001)。女性年龄较大(P<0.001),CCI 较低(P<0.001),更有可能接受 TAVR(P<0.001),住院死亡率较高(TAVR,P=0.015;SAVR,P<0.001),尽管调整了年龄和 CCI,但仍持续存在。
在法国,TAVR 在年轻患者中仍然不常见,主要限于高危患者。在患者人口统计学特征、AVR 方式选择和患者结局方面观察到重要的性别差异。需要进一步研究评估 TAVR 在年轻患者中的长期影响,以及前瞻性数据评估 AVR 方式选择和结局的性别差异。